Navidea signs immunotherapy deal with IMV

By staff writers

November 7, 2019 -- Radiopharmaceutical developer Navidea Biopharmaceuticals has signed an agreement with biopharmaceutical company IMV to explore a preclinical research collaboration that could combine each company's immunotherapy technologies.

The goal of the collaboration is to perform preclinical research studies that evaluate the combination of Navidea's CD206-activated macrophage-targeting therapeutics with IMV's DPX-based immunotherapies. Both companies will jointly conduct the research throughout the duration of the study.

The companies believe the joint research could lead to new approaches to treating a variety of cancers.

Copyright © 2019

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking